CNTY-107 / Century Therap - LARVOL DELTA

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain. The VHH antibodies were engineered into CAR formats and characterized for expression, cell activation through antigen engagement, and cytotoxicity activity in primary T cells. Selected binders demonstrated efficacy in multiple CAR formats in primary T cells in a mouse xenograft model using OVCar-3 tumor cells."

Preclinical • Oncology • Ovarian Cancer • Solid Tumor

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire) - "Century Therapeutics...announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026. The resulting changes include de-prioritizing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will prioritize key programs, including one follow-on product candidate for lymphoma, CNTY-102, and CNTY-107, a product candidate for Nectin-4+ tumors. In addition, Century will continue its partnered programs with Bristol Myers Squibb with no impact to previous guidance on timelines."

Pipeline update • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) - "Pipeline Updates: The Company today provided an update on its solid tumor strategy, including the nomination of its next pipeline program, CNTY-107, a Nectin-4 CAR γδ iT product candidate. The Company expects to file an Investigational New Drug (IND) Application in 2025 for Nectin-4+ cancers."

IND • Pipeline update • Oncology